A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402

British Journal of Haematology

Volumn 170, Issue 5, 2015, Pages 679-686

  Witzig, Thomas E ^a   Hong, Fangxin ^b   Micallef, Ivana N ^a   Gascoyne, Randy D ^c   Dogan, Ahmet ^a,g   Wagner, Henry ^d   Kahl, Brad S ^e   Advani, Ranjana H ^f   Horning, Sandra J ^f,h  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d PENN STATE CANCER INSTITUTE   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f STANFORD UNIVERSITY   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h GENENTECH INC   (United States)

Author keywords

Large cell lymphoma; R CHOP; Radioimmunotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN IN 111; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; AGED; ANEMIA; ARTICLE; BASAL CELL CARCINOMA; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; EARLY CANCER; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; INVOLVED FIELD RADIOTHERAPY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NON MELANOMA SKIN CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; THERAPY DELAY; THERAPY EFFECT; THROMBOCYTOPENIA; THYROID CARCINOMA; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; SURVIVAL RATE; VINCRISTINE;

EID: 84938960997     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13493     Document Type: Article

References (25)

1. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, Jr, J., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. & Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-511.
2. Cheson, B., Horning, S., Coiffier, B., Shipp, M., Fisher, R., Connors, J., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N., Armitage, J., Carter, W., Hoppe, R. & Canellos, G. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. Journal of Clinical Oncology, 17, 1244-1253.
3. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
4. Cheson, B.D., Fisher, R.I., Barrington, S.F., Cavalli, F., Schwartz, L.H. & Lister, T.A., Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology, 32, 3059-3068.
5. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
6. Drake, M.T., Maurer, M.J., Link, B.K., Habermann, T.M., Ansell, S.M., Micallef, I.N., Kelly, J.L., Macon, W.R., Nowakowski, G.S., Inwards, D.J., Johnston, P.B., Singh, R.J., Allmer, C., Slager, S.L., Weiner, G.J., Witzig, T.E. & Cerhan, J.R. (2010) Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. Journal of Clinical Oncology, 28, 4191-4198.
7. Friedberg, J.W., Unger, J.M., Burack, W.R., Gopal, A.K., Raju, R.N., Nademanee, A.P., Kaminski, M.S., Li, H., Press, O.W., Miller, T.P. & Fisher, R.I. (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. British Journal of Haematology, 166, 382-389.
8. Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. & Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 3121-3127.
9. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
10. Horning, S.J., Weller, E., Kim, K., Earle, J.D., O'Connell, M.J., Habermann, T.M. & Glick, J.H. (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. Journal of Clinical Oncology, 22, 3032-3038.
11. Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C. & Staudt, L.M.; Lymphoma/Leukemia Molecular Profiling Project. (2008) Stromal gene signatures in large-B-cell lymphomas. New England Journal of Medicine, 359, 2313-2323.
12. Maurer, M.J., Ghesquieres, H., Jais, J.P., Witzig, T.E., Haioun, C., Thompson, C.A., Delarue, R., Micallef, I.N., Peyrade, F., Macon, W.R., Jo Molina, T., Ketterer, N., Syrbu, S.I., Fitoussi, O., Kurtin, P.J., Allmer, C., Nicolas-Virelizier, E., Slager, S.L., Habermann, T.M., Link, B.K., Salles, G., Tilly, H. & Cerhan, J.R. (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. Journal of Clinical Oncology, 32, 1066-1073.
13. Maurer, M.J., Micallef, I.N., Cerhan, J.R., Katzmann, J.A., Link, B.K., Colgan, J.P., Habermann, T.M., Inwards, D.J., Markovic, S.N., Ansell, S.M., Porrata, L.F., Johnston, P.B., Nowakowski, G.S., Thompson, C.A., Gupta, M., Syrbu, S.I., Kurtin, P.J., Macon, W.R., Nikcevich, D.A. & Witzig, T.E. (2011) Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 29, 1620-1626.
14. Micallef, I.N., Maurer, M.J., Wiseman, G.A., Nikcevich, D.A., Kurtin, P.J., Cannon, M.W., Perez, D.G., Soori, G.S., Link, B.K., Habermann, T.M. & Witzig, T.E. (2011) Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood, 118, 4053-4061.
15. Miller, T.P., Dahlberg, S., Cassady, J.R., Adelstein, D.J., Spier, C.M., Grogan, T.M., LeBlanc, M., Carlin, S., Chase, E. & Fisher, R.I. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. New England Journal of Medicine, 339, 21-26.
16. Miller, T.P., LeBlanc, M., Spier, C., Chase, E. & Fischer, R.I. (2001) CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood (American Society of Hematology Annual Meeting Abstracts), 98, 724a.
17. Miller, T.P., Unger, J.M., Spier, C., Stea, B., Press, O.W., Friedberg, J.W., LeBlanc, M. & Fisher, R.I. (2008) Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313). Blood (American Society of Hematology Annual Meeting Abstracts), 112, 3598.
18. Persky, D.O., Unger, J.M., Spier, C.M., Stea, B., LeBlanc, M., McCarty, M.J., Rimsza, L.M., Fisher, R.I. & Miller, T.P. (2008) Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. Journal of Clinical Oncology, 26, 2258-2263.
19. Pfreundschuh, M., Kuhnt, E., Trumper, L., Osterborg, A., Trneny, M., Shepherd, L., Gill, D.S., Walewski, J., Pettengell, R., Jaeger, U., Zinzani, P.L., Shpilberg, O., Kvaloy, S., de Nully Brown, P., Stahel, R., Milpied, N., Lopez-Guillermo, A., Poeschel, V., Grass, S., Loeffler, M. & Murawski, N.; for the MabThera International Trial Group. (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet. Oncology, 12, 1013-1022.
20. Phan, J., Mazloom, A., Medeiros, L.J., Zreik, T.G., Wogan, C., Shihadeh, F., Rodriguez, M.A., Fayad, L., Fowler, N., Reed, V., Horace, P. & Dabaja, B.S. (2010) Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. Journal of Clinical Oncology, 28, 4170-4176.
21. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. & Staudt, L.M. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 1937-1947.
22. Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R.D., Chan, W.C., Zhao, T., Haioun, C., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Campo, E., Montserrat, E., Lopez-Guillermo, A., Ott, G., Muller-Hermelink, H.K., Connors, J.M., Braziel, R., Grogan, T.M., Fisher, R.I., Miller, T.P., LeBlanc, M., Chiorazzi, M., Zhao, H., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D. & Staudt, L.M. (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. Journal of Experimental Medicine, 198, 851-862.
23. Shenkier, T.N., Voss, N., Fairey, R., Gascoyne, R.D., Hoskins, P., Klasa, R., Klimo, P., O'Reilly, S.E., Sutcliffe, S. & Connors, J.M. (2002) Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. Journal of Clinical Oncology, 20, 197-204.
24. Vaidya, R. & Witzig, T.E. (2014) Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Annals of Oncology, 25, 2124-2133.
25. Yahalom, J. (2010) Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains. Journal of Clinical Oncology, 28, 4105-4107.